Spotlight on Latin America: Closing the Gap
Cynthia Villarreal-Garza, MD, DSc
The Future of Oral SERDs: Combination Strategies
Komal Jhaveri, MD, FACP
Routes Reconsidered: A Case-Based Debate in SERD Selection
Giuseppe Curigliano, MD, PhD
Spotlight on Asia-Pacific: Practice Beyond Borders
Hiraji Iwata, MD, PhD
From Data to Debate: Global Perspectives on HR+/HER2- mBC Care
Spotlight on Europe: Adapting the Evidence
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Unmet Needs in Endocrine Therapy: Rethinking the HR+/HER2- mBC Treatment Roadmap
Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
Doublet or Triplet? A Case-Based Debate in First-Line Choices for HR+/HER2- mBC
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
Javier Cortes, MD, PhD
Hope S. Rugo, MD, FASCO
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
Peter Schmid, FRCP, MD, PhD
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Erica L. Mayer, MD, MPH
Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer
William J. Gradishar, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.